Efficacy and Safety of Dotinurad in Patients with Advanced Chronic Kidney Disease

Efficacy and Safety of Dotinurad in Patients with Advanced Chronic Kidney Disease - Efficacy and Safety of Dotinurad in Patients with Advanced Chronic Kidney Disease

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000057381

Enrollment

Registered

2025-03-25

Start date

2022-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic kidney disease patients with hyperuricemia

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who visited Ibaraki Prefectural Central Hospital and Ibaraki Regional Cancer Center as outpatients between April 2022 and September 2024 and were prescribed dotinurad for hyperuricemia were included. Patients were selected if their estimated glomerular filtration rate (eGFR) was less than 45 mL/min/1.73 m2 at the time of administration, and serum creatinine and serum uric acid levels could be evaluated 6 months before and after administration.

Exclusion criteria

Exclusion criteria: Patients who had a new intervention of other drugs after the start of dothinurad were excluded.

Design outcomes

Primary

Measure	Time frame
Serum uric acid level after 6 months of treatment with Dotinurad	—

Secondary

Measure	Time frame
eGFR at 6 months before and after dothinurad administration	—

Countries

Japan

Contacts

Public ContactTeppei Motomura

Ibaraki prefectural central hospital,Ibraki cancer center Nephrology

teppei621621@gmail.com0296771121

Outcome results